The Food and Drug Administration (FDA) has recently approved a third updated Covid-19 vaccine for distribution this fall, which is manufactured by Novavax. This news comes as Pfizer and Moderna have already started shipping modified doses of their vaccines to better match the evolving strains of the coronavirus. These updated doses are suitable for both adults and children as young as 6 months old.
The newly approved Novavax vaccine is available for individuals aged 12 and older. Despite the existing immunity in the population due to prior infections or vaccinations, health officials warn that this protection may diminish over time. With the approaching winter season, which typically sees a surge in Covid-19 cases, it is crucial for Americans to get vaccinated with one of the available options this fall.
Unlike the mRNA technology used in Pfizer and Moderna vaccines, Novavax utilizes a protein-based vaccine combined with an immune booster. Additionally, there is a slight difference in the formulations this year. While Pfizer and Moderna vaccines are designed to target the KP.2 virus subtype, the Novavax formula focuses on the parent strain, JN.1. The FDA has confirmed that both formulations offer cross-protection against the currently circulating strains of the virus.
As the vaccination campaign continues, it is important to stay informed about the latest updates and recommendations from health authorities. The availability of multiple vaccine options provides individuals with choices to protect themselves and their communities from Covid-19. By getting vaccinated, individuals can contribute to the ongoing efforts to control the spread of the virus and achieve herd immunity.
The approval of the updated Novavax vaccine adds another valuable tool to the arsenal of Covid-19 vaccines, further enhancing the vaccination campaign and bolstering immunity in the population. It is essential for everyone eligible to receive the vaccine to consider getting vaccinated to safeguard their health and the well-being of others.
